258 related articles for article (PubMed ID: 34606520)
1. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
[TBL] [Abstract][Full Text] [Related]
2. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
3. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
Kohli M; Maschio M; Becker D; Weinstein MC
Vaccine; 2021 Feb; 39(7):1157-1164. PubMed ID: 33483216
[TBL] [Abstract][Full Text] [Related]
7. Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region.
Liu Y; Sandmann FG; Barnard RC; Pearson CAB; ; Pastore R; Pebody R; Flasche S; Jit M
medRxiv; 2021 Jul; ():. PubMed ID: 34282421
[TBL] [Abstract][Full Text] [Related]
8. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study.
Savinkina A; Bilinski A; Fitzpatrick M; Paltiel AD; Rizvi Z; Salomon J; Thornhill T; Gonsalves G
BMJ Open; 2022 Sep; 12(9):e061752. PubMed ID: 36100306
[TBL] [Abstract][Full Text] [Related]
9. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.
Mar J; Ibarrondo O; Estadilla CDS; Stollenwerk N; Antoñanzas F; Blasco-Aguado R; Larrañaga I; Bidaurrazaga J; Aguiar M
Pharmacoeconomics; 2024 Feb; 42(2):219-229. PubMed ID: 37910377
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries.
Obeng-Kusi M; Habila MA; Roe DJ; Erstad B; Abraham I
J Med Econ; 2021 Nov; 24(sup1):1-13. PubMed ID: 34866541
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
14. Modelling the Cost-Effectiveness of Hepatitis A in South Africa.
Patterson J; Cleary S; Norman JM; Van Zyl H; Awine T; Mayet S; Kagina B; Muloiwa R; Hussey G; Silal SP
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400100
[TBL] [Abstract][Full Text] [Related]
15. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
[TBL] [Abstract][Full Text] [Related]
16. The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model.
Knerer G; Currie CSM; Brailsford SC
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008805. PubMed ID: 33095791
[TBL] [Abstract][Full Text] [Related]
17. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.
Moore S; Hill EM; Tildesley MJ; Dyson L; Keeling MJ
Lancet Infect Dis; 2021 Jun; 21(6):793-802. PubMed ID: 33743847
[TBL] [Abstract][Full Text] [Related]
18. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
20. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]